The Animal Experimental Center currently has an animal room area of 6600 square meters, including breeding and experimental facilities for both normal environments (mice, rats, guinea pigs, rabbits, dogs, cats, miniature pigs, monkeys) and barrier environments (mice, rats, guinea pigs, hamsters). It has experimental equipment for animal behavior, imaging, pathology, biochemistry, molecular biology, and electrophysiology, and is responsible for the management and use of experimental animals, animal ethics, and welfare protection Functions such as animal experimental technology training.

Since its establishment, Tiancheng has established an independent quality assurance department to ensure that the company operates under a quality system that complies with GLP regulations. The Quality Assurance Department is responsible for the construction and maintenance of our company's quality system, conducting daily facility based, process based, and research based inspections to ensure compliance with GLP requirements; Responsible for the quality assurance work of the company's research topics, covering all fields such as non clinical safety evaluation, pharmacodynamic research, and pharmacokinetic research; Participate in SOP development, review and archive; Responsible for evaluating external entrusted institutions to ensure that their quality system meets the quality management requirements of the company and research and development projects.

The GLP Management Center is responsible for the design, technical consultation, and commercial and technical negotiations of project proposals undertaken by the company; Fully responsible for the management of the company's experimental projects, including the appointment, submission, and progress supervision of both horizontal and vertical projects, as well as the input, update, and statistics of project related information to ensure the smooth progress of each project; Responsible for the company's intellectual property management, instrument and equipment management, scientific research application, leading the construction of GLP institutions, system and process construction, academic research system construction, discipline field talent team construction, relevant internal and external coordination, and resource coordination.

The Test Article Management and Analysis Center provides test article analysis services for chemical drugs, traditional Chinese medicine, and biological products. A comprehensive management system for test samples has been established, with independent test sample management and preparation laboratories, and a dedicated darkroom (yellow light illumination) for the preparation of dark drugs. The laboratory is equipped with drying cabinets, refrigerated refrigerators, low-temperature refrigerators, liquid nitrogen tanks, clean workstations, etc., which can meet the requirements for the preservation and preparation of chemical drugs, traditional Chinese medicine, and biological products. Research scope: 1 Analysis of test samples for chemical drugs, traditional Chinese medicine, and biological products: development, transfer, optimization, and validation of methods such as high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS/MS); Homogeneity, stability, and concentration or content determination of the test sample after preparation. 2. Analysis of test samples for cell drugs: Cell viability and cell suspension concentration of stem cell products were measured using a cell counter combined with an inverted optical microscope (cell counting plate) and trypan blue staining method. 3. Test article analysis of special preparations: gel preparations shall be extracted with appropriate solvent and determined by HPLC or LC-MS/MS for content, homogeneity and stability; Inhalation of the preparation, selection of appropriate good solvents for scientific collection of the analyte (aerosol collected using filter paper adsorption method), combined with HPLC or LC-MS/MS method for content, uniformity, and stability determination.

The research field of the Biopharmaceutical Analysis Center covers the evaluation of non clinical and clinical pharmacokinetics, immunogenicity, and toxicokinetics of biotechnology drugs. The research content includes: 1 Non clinical and clinical PK/PD studies on new biological products such as proteins, peptides, or antibodies: Quantitative detection methods such as hypersensitive multi factor electrochemical luminescence analysis (MSD), enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and isotope tracing have been established for pharmacokinetic, tissue distribution, and excretion studies. 2. Non clinical safety evaluation of biotechnology innovative drugs: Establish an immunogenicity research system, combine long-term toxicity with toxicokinetics, and other research methods to evaluate the safety of multiple new drugs such as monoclonal antibodies, fusion proteins, enzymes, hormones, cytokines, etc. (toxicokinetics, immunogenicity, etc.). More than 60 non clinical safety evaluations of innovative biotechnology drugs have been completed in total. More than 10 products have been launched, and multiple new drugs have completed Phase III clinical trials, providing a cutting-edge technology platform for the research and evaluation of innovative biotechnology drugs.

The Clinical Laboratory and Pathology Center undertakes clinical and histopathological examinations for rodents, non rodents, and non human primates, including single toxicity tests, repeated toxicity tests, local toxicity tests, reproductive toxicity tests, carcinogenic tests, and pharmacodynamic tests. It also conducts comprehensive analysis and judgment on the test results to determine the toxic target organs and sites of the evaluated drug, ensuring an objective evaluation of the safety of the new drug, We have completed over 600 research projects on the toxicity and pathology of new drugs, with a total of hundreds of thousands of pathological films reviewed. We have a deep technical level and rich project experience.

The Pharmacodynamics Research Center has decades of research experience, formerly known as the "Tianjin Hypertension Pharmacodynamics Laboratory of the New Drug Research and Management Center of the State Pharmaceutical Administration" established in 1993 and the "State Key Laboratory of Pharmacokinetics and Pharmacodynamics co built by the Ministry and the Province" established in 2001. The center has complete research facilities and equipment, including various surgical related equipment, signal acquisition systems, imaging and behavioral testing instruments, etc. The pharmacodynamics research team has rich research and development experience, proficient in mature modeling techniques for over 300 pharmacodynamic models, especially in the fields of tumor, cardiovascular, neurological, metabolic and other pharmacodynamics research. Nearly 400 preclinical pharmacodynamic research projects have been completed, helping to approve over 70 clinical and marketed products.

The Pharmacokinetic Research Center originated from the Pharmacokinetic Laboratory established by Academician Changxiao Liu in 1968. It is the oldest professional institution in pharmacokinetics in China, gathering the wisdom and experience of several generations of researchers. During the "Ninth Five Year Plan" to "13th Five Year Plan" period, it successfully completed multiple national level major scientific and technological projects and established a high-level preclinical pharmacokinetic evaluation and research technology platform, These include the "Technical Platform for in vitro and in vivo Pharmacokinetic Evaluation and Research of Chemical Drugs", the "Technical Platform for in vitro and in vivo Pharmacokinetic Evaluation and Research of Biotechnology Drugs", the "Technical Platform for in vivo and in vitro Pharmacokinetic Evaluation and Research of Traditional Chinese Medicine and Natural Products", the "Technical Platform for Toxicokinetics Research", and the "Technical Platform for Drug Transporter Research", Completed pharmacokinetic studies on over 300 new drugs in total. The Center is also the core unit of the State Key Laboratory of Drug Release Technology and Pharmacokinetics. This laboratory was approved by the Ministry of Science and Technology of the People's Republic of China in December 2010 and is a affiliated unit of the Drug Metabolism Professional Committee of the Chinese Pharmacological Society (CSSX). It has jointly established an office with the International Society of Pharmacology (ISSX) and has become the first national level close partner of ISSX in the world.

The research and development system of the Toxicology Research Center can be traced back to the 1960s. In the early stages of China's pharmaceutical industry, it undertook several national major toxicological research on new drugs and won multiple national invention awards. In 1992, it participated in the drafting of the first version of the National Medical Administration's quality management standards for non clinical drug safety research. The company obtained GLP certification for the first time in 2007 and successfully passed re certification in 2010, 2013, 2017, and 2020. According to the guiding principles of CDE and ICH, it can provide scheme design and research reports that meet the regulatory requirements of China's NMPA, the United States FDA, and other countries. It has completed over 600 non clinical safety evaluation projects, covering various biological products, chemical drugs, and traditional Chinese medicine, such as cell drugs, recombinant proteins, antibody drugs, vaccines, etc Chemical targeted medicine, traditional Chinese patent medicines and simple preparations, Chinese herbal pieces, etc.